Clene Inc. (CLNN)
Automate Your Wheel Strategy on CLNN
With Tiblio's Option Bot, you can configure your own wheel strategy including CLNN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CLNN
- Rev/Share 0.0397
- Book/Share -0.5635
- PB -6.9561
- Debt/Equity -4.2109
- CurrentRatio 1.363
- ROIC -1.4975
- MktCap 35212380.0
- FreeCF/Share -2.1824
- PFCF -1.8284
- PE -1.1899
- Debt/Assets 0.8272
- DivYield 0
- ROE 6.2996
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Clene Inc. (CLNN) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $1.80 per share a year ago.
Read More
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SALT LAKE CITY, March 24, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its full year 2024 financial results and provided recent operating highlights for the clinical programs in ALS and MS.
Read More
Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkers APST Research data includes thousands of people living with ALS including clinical, survival, and longitudinal NfL data Clene plans to analyze the APST ALS NfL biomarker and clinical dataset to compare NfL change from its ongoing NIH-sponsored EAP to address the FDA's request for supportive evidence of CNM-Au8's effect on NfL reduction observed in the HEALEY ALS Platform Trial Clene plans to submit a New Drug Application (NDA) in second-half 2025 SALT LAKE CITY, Feb. 25, 2025 (GLOBE NEWSWIRE) …
Read More
About Clene Inc. (CLNN)
- IPO Date 2018-10-18
- Website https://clene.com
- Industry Biotechnology
- CEO Mr. Robert Etherington MBA
- Employees 75